Alivus Life

Why is Alivus Life Sciences Ltd falling/rising?

As of 30-Jul, Alivus Life Sciences Ltd's stock price is declining, currently at 1,095.45, reflecting a 2.17% decrease. Despite strong fundamentals, recent trading activity shows a lack of investor confidence, with significant drops in participation and performance compared to the benchmark Sensex.

As of 30-Jul, Alivus Life Sciences Ltd's stock price is falling, currently at 1,095.45, which reflects a decrease of 24.25 or 2.17%. This decline is evident in the stock's performance over the past week and month, where it has underperformed the benchmark Sensex, showing a drop of 0.78% over one week and 5.24% over one month, while the Sensex has gained 2.01% and 1.90%, respectively. <BR><BR>Today's trading activity indicates a negative trend, with the stock touching an intraday low of Rs 1,090.1, representing a decrease of 2.64%. Additionally, the stock has seen a significant drop in investor participation, with delivery volume falling by 48.67% compared to the five-day average. Although the stock is trading above its 50-day, 100-day, and 200-day moving averages, it is below its 5-day and 20-day moving averages, suggesting a short-term weakness.<BR><BR>Despite the company's strong fundamentals, such as being net-debt free and having a high return on equity (ROE) of 19.43%, the recent price movements indicate a lack of investor confidence in the short term, contributing to the stock's decline.

Which are the latest news on Alivus Life?

Should I buy, sell or hold Alivus Life Sciences Ltd?

When is the next results date for Alivus Life Sciences Ltd?

The next results date for Alivus Life Sciences Ltd is 30 July 2026.

The next results date for Alivus Life Sciences Ltd is scheduled for 30 July 2026.

What does Alivus Life do?

Alivus Life Sciences Ltd is a small-cap company in the Pharmaceuticals & Biotechnology sector, reporting net sales of 689 Cr and a net profit of 163 Cr for the quarter ending March 2026. Key metrics include a P/E ratio of 22.00 and a market cap of INR 12,802 Cr.

Overview: <BR>Alivus Life Sciences Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Small Cap company.<BR><BR>History: <BR>Alivus Life Sciences Limited was initially established as 'Zorg Laboratories Private Limited' on June 23, 2011. The company was granted the Certificate of Incorporation by the Registrar of Companies, Maharashtra in Pune. The latest quarterly results report net sales and profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 689 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 163 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 12,802 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 22.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.48% <BR>Debt Equity: -0.22 <BR>Return on Equity: 17.52% <BR>Price to Book: 3.80 <BR><BR>Contact Details: <BR>No Company Details Available <BR>Registrar Address: Not available.

How big is Alivus Life?

As of 10th June, Alivus Life Sciences Ltd has a market capitalization of 12,802.00 Cr, with recent net sales of 2551.84 Cr and net profit of 564.49 Cr over the last four quarters.

As of 10th June, <BR><BR>Market Cap: Alivus Life Sciences Ltd has a market capitalization of 12,802.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters amounts to 2551.84 Cr, while the sum of Net Profit for the same period is 564.49 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025. Shareholder's Funds are valued at 2,817.37 Cr, and Total Assets stand at 3,411.45 Cr.

Who are in the management team of Alivus Life?

The management team of Alivus Life includes Chairman Glenn Saldanha, Managing Director & CEO Yasir Yusufali Rawjee, and several Non-Executive and Independent Directors, bringing diverse expertise to the company.

The management team of Alivus Life includes the following key members:<BR><BR>1. **Glenn Saldanha** - Chairman & Non-Executive Director<BR>2. **V S Mani** - Non-Executive Director<BR>3. **Yasir Yusufali Rawjee** - Managing Director & CEO<BR>4. **Vinod Naik** - Executive Director & Wholetime Director<BR>5. **Sridhar Gorthi** - Independent Non-Executive Director<BR>6. **Manju Agarwal** - Independent Non-Executive Director<BR>7. **Taruvai Laxminarayanan Easwar** - Independent Non-Executive Director<BR>8. **Gita Nayyar** - Independent Non-Executive Director<BR><BR>This team brings a diverse range of experience and expertise to the company.

Who are the peers of the Alivus Life?

Alivus Life's peers include Cohance Life, Natco Pharma, Jubilant Pharmo, Alembic Pharma, Concord Biotech, Marksans Pharma, Shilpa Medicare, Viyash Scientifi, and Sanofi Consumer. Most peers have Below Average growth and management risk, with Alivus Life showing better performance in 1-year returns compared to Cohance Life but lower than Marksans Pharma.

Peers: The peers of Alivus Life are Cohance Life, Natco Pharma, Jubilant Pharmo, Alembic Pharma, Concord Biotech, Marksans Pharma, Shilpa Medicare, Viyash Scientifi, and Sanofi Consumer.<BR><BR>Quality Snapshot: Excellent management risk is observed at Cohance Life, Alembic Pharma, Concord Biotech, Alivus Life, Marksans Pharma, and Sanofi Consumer, while Good management risk is found at Natco Pharma and Shilpa Medicare. Average management risk is present at Jubilant Pharmo and Viyash Scientifi, and the rest have Below Average management risk. All peers exhibit Below Average growth except for Alivus Life, Cohance Life, Alembic Pharma, Concord Biotech, Marksans Pharma, and Sanofi Consumer, which have Excellent capital structure, while the rest have Average or Below Average capital structure.<BR><BR>Return Snapshot: Marksans Pharma has the highest 1-year return at -3.60%, while Cohance Life has the lowest at -57.78%. Alivus Life's 1-year return of 0.50% is better than Cohance Life's but lower than Marksans Pharma's. Additionally, the peers with negative six-month returns include Cohance Life, Jubilant Pharmo, Alembic Pharma, and Concord Biotech.

Are Alivus Life Sciences Ltd latest results good or bad?

Alivus Life Sciences Ltd's latest results show a net profit increase of 14.66% and revenue growth of 6.09%, indicating solid sales performance. However, concerns arise from a significant decline in operating margins and slowing revenue growth, which investors should monitor closely.

Alivus Life Sciences Ltd's latest results present a mixed picture. On the positive side, the company reported a net profit of ₹162.66 crores for Q4 FY26, which is a 14.66% increase year-on-year, and a revenue of ₹689.12 crores, reflecting a 6.09% year-on-year growth. This indicates that the company is maintaining a solid profit trajectory and achieving record quarterly sales.<BR><BR>However, there are notable concerns regarding operational efficiency. The operating margin, excluding other income, has contracted significantly from 34.37% in the previous quarter to 31.13% in Q4 FY26. This decline raises questions about the company's ability to manage costs effectively in a competitive market. Additionally, the revenue growth has slowed compared to previous quarters, suggesting potential challenges in sustaining demand.<BR><BR>Overall, while the profit growth and sales figures are encouraging, the margin compression and deceleration in revenue growth are issues that investors should monitor closely. The company's strong capital efficiency, evidenced by a return on equity of 18.73% and a zero-debt balance sheet, provides a solid foundation, but the operational challenges could impact future performance.

Is Alivus Life overvalued or undervalued?

As of December 4, 2025, Alivus Life is considered an attractive investment due to its undervalued status with a PE ratio of 20.10, strong operational efficiency indicated by a ROCE of 27.80% and ROE of 17.59%, and a favorable PEG ratio of 0.80 compared to peers, despite a year-to-date stock performance lagging behind the Sensex.

As of 4 December 2025, Alivus Life has moved from a fair to an attractive valuation grade. The company is currently considered undervalued, with a PE ratio of 20.10, a Price to Book Value of 3.53, and an EV to EBITDA of 13.60. In comparison to peers, Alivus Life's PEG ratio of 0.80 suggests it is more favorably priced relative to growth than competitors like Sun Pharma, which has a PE of 37.78, and Divi's Lab, with a PE of 68.56.<BR><BR>Despite recent stock performance lagging behind the Sensex, with a year-to-date return of -12.15% compared to the Sensex's 9.12%, the strong ROCE of 27.80% and ROE of 17.59% indicate robust operational efficiency. Overall, the metrics suggest that Alivus Life is positioned well within the pharmaceuticals and biotechnology sector, making it an attractive investment opportunity.

Is Alivus Life technically bullish or bearish?

As of December 2, 2025, the market trend has shifted to a moderately strong bearish stance, indicated by bearish MACD, moving averages, and KST on the weekly chart, along with bearish Bollinger Bands, while the RSI and Dow Theory show no immediate reversal signals.

As of 2 December 2025, the technical trend has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this include a bearish MACD on the weekly chart, bearish moving averages on the daily timeframe, and a bearish KST on the weekly chart. The Bollinger Bands are also indicating a bearish trend on the weekly timeframe. Overall, the lack of significant signals from the RSI and Dow Theory suggests a continuation of the bearish sentiment without any immediate reversal signals.

How has been the historical performance of Alivus Life?

Alivus Life has shown consistent growth over the past six years, with net sales increasing from 1,537.31 Cr in March 2020 to 2,386.88 Cr in March 2025, and profit after tax rising from 313.10 Cr to 485.63 Cr. Total assets also grew significantly from 1,725.60 Cr to 3,411.45 Cr, reflecting a strong expansion strategy.

Answer:<BR>The historical performance of Alivus Life shows a consistent growth trend in net sales and profits over the past six years, culminating in a profit after tax of 485.63 Cr for the year ending March 2025.<BR><BR>Breakdown:<BR>Alivus Life has demonstrated a steady increase in net sales, rising from 1,537.31 Cr in March 2020 to 2,386.88 Cr in March 2025. The total operating income followed a similar trajectory, reaching 2,386.88 Cr in March 2025, up from 1,537.31 Cr in March 2020. Operating profit, excluding other income, also saw growth, increasing from 471.96 Cr in March 2020 to 682.58 Cr in March 2025. The profit before tax reached 654.13 Cr in March 2025, while profit after tax increased from 313.10 Cr in March 2020 to 485.63 Cr in March 2025. The company's total assets grew significantly from 1,725.60 Cr in March 2020 to 3,411.45 Cr in March 2025, reflecting a robust expansion strategy. Meanwhile, total liabilities increased from 1,725.60 Cr to 3,411.45 Cr over the same period, indicating a proportional rise in obligations alongside asset growth. Cash flow from operating activities showed a positive trend, although the net cash outflow in March 2025 was -230.00 Cr, down from a net inflow of 17.00 Cr in March 2024. Overall, Alivus Life's financial metrics indicate a strong upward trajectory in both revenue and profitability, despite some fluctuations in cash flow.

Who are the top shareholders of the Alivus Life?

The top shareholders of Alivus Life include Nirma Limited with 74.99%, followed by 71 Foreign Institutional Investors holding 6.57%, and 18 mutual fund schemes at 3.59%. Individual investors own 10.5%, while Polar Capital Funds Plc - Healthcare Opportunities is the largest public shareholder with 2.79%.

The top shareholders of Alivus Life include Nirma Limited, which holds the largest stake at 74.99%. Other significant shareholders are 71 Foreign Institutional Investors (FIIs) with a combined holding of 6.57%, and 18 mutual fund schemes that account for 3.59%. Additionally, Polar Capital Funds Plc - Healthcare Opportunities is the highest public shareholder, holding 2.79%. Individual investors collectively own 10.5% of the company.

Has Alivus Life declared dividend?

Alivus Life Sciences Ltd has declared a 1125% dividend, amounting to 22.5 per share, with an ex-date of October 17, 2023. Despite the significant dividend declaration, the dividend yield is 0%, and total returns have varied, showing strong performance over longer periods but negative returns in the last 6 months.

Alivus Life Sciences Ltd has declared a 1125% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 1125%<BR>- Amount per share: 22.5<BR>- Ex-date: Oct-17-2023<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -4.81%, with a dividend return of 0%, resulting in a total return of -4.81%.<BR><BR>Over the past year, the price return was 18.32%, with a dividend return of 0%, leading to a total return of 18.32%.<BR><BR>In the 2-year period, the price return was 84.65%, the dividend return was 3.79%, and the total return was 88.44%.<BR><BR>For the 3-year period, the price return was 119.17%, the dividend return was 12.28%, resulting in a total return of 131.45%.<BR><BR>In the 4-year period, there was no price return, no dividend return, and a total return of 0.0%.<BR><BR>Over the last 5 years, the price return was 0%, the dividend return was 0%, leading to a total return of 0.0%.<BR><BR>Overall, Alivus Life has declared a significant dividend, but the dividend yield remains at 0%. The total returns show a mixed performance, with strong returns over longer periods but negative returns in the shorter term.